In EGFR-amplified glioblastoma, palmitoylation of SETD2 mediated by ZDHHC16 protects SETD2 from degradation and, thereby, facilitates its role in mediating DNA damage response and repressing cancer initiation (Figure 6e) [159]. This evidence concerns the gene SETD2 and cancer.